Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPO301 in Advanced or Metastatic Solid Tumors
NCT05948865Phase 1Recruiting
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CPO301 in solid tumor, non-small cell lung cancer (NSCLC), breast cancer and 2 more (2 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoints: Recommended Phase 2 Dose at 1 year and Safety and tolerability at RP2D at 1 year. Started Jun 2023; status: recruiting.
02
Drugs
CPO301
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancercolorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05948865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948865.